SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Omeros
An SI Board Since March 2010
Posts SubjectMarks Bans Symbol
464 28 0 OMER
Emcee:  Bradpalm1 Type:  Unmoderated
Introduction Market Data Compact
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery™ platform and one from its Addiction program, the most advanced of which is in Phase 3 clinical trials. Omeros may also have the near-term capability, through its GPCR (G-protein coupled receptor) program, to add an unprecedented number of wholly new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody and small-molecule preclinical programs targeting inflammation and central nervous system disorders.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
464But the company apparently refused to specify the number of patients or the resptuck-12/4/2019
463Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal TJulius Wong-12/4/2019
462From today's announcement: Omeros’ preliminary (unaudited) total and OMIDRInigel bates-1/14/2019
461[graphic]Julius Wong-5/12/2018
460Omeros Corporation: Substantial Value Added To The HSCT-TMA Franchise seekingalJulius Wong-4/29/2018
459>> Snicker << Message 31555019scaram(o)uche-4/3/2018
458Omeros Spikes 37% Amid Favorable Medicare Policy In Congressional Spending Bill Julius Wong-3/22/2018
457Crickets...... clinicaltrials.govscaram(o)uche-3/12/2018
456721 fails to get priority review in Europe in a couple of indications. Recommentuck13/2/2018
455What's a mere five years, Greg? That GPCR franchise is just awesome, a realscaram(o)uche-3/1/2018
454prnewswire.com -- Clinical Entry Planned for Second Half of 2013 -- From todascaram(o)uche-3/1/2018
453Disingenuous, Greg. Until it's here, it ain't...... clinicaltrials.govscaram(o)uche-3/1/2018
452>> Patient enrollment is expected to begin early next month << Goesscaram(o)uche-2/22/2018
451Omeros gets panned Finally, shares of Omeros plunged nearly 18%. The small bioteJulius Wong-2/15/2018
450I haven't been a shareholder. Just bought a small stake. Greg has over proscaram(o)uche-2/14/2018
449SEATTLE--(BUSINESS WIRE)--Jan. 3, 2018-- Omeros Corporation (Nasdaq: OMER) todaynigel bates-1/3/2018
448Omeros' OMIDRIA Eye Drop OK'ed For Pediatric Use finance.yahoo.comJulius Wong-12/13/2017
447Press Release Omeros Corporation to Announce Third Quarter 2017 Financial ResulBiotech Jim-11/6/2017
446Was curious about sales of Omridia. In the area I reside, it does not seem to beD.Lu-11/6/2017
445Bloomberg has this to say last week for products coming up for Pass Through StatBiotech Jim111/5/2017
444I just saw on Twitter that AF is now saying Omridia will lose Medicare pass-thoutuck-11/3/2017
443Deleted Mistaken PostBulbaMan-9/26/2017
442On watch for clear above 21.59. [graphic]hollyhunter-9/20/2017
441OMER responds to AF, a one time event? Some )MS 721 trials info updated here. Biotech Jim-8/23/2017
440A bit different. Prices at 22.75, and asks pop up below that. Decent pricing, scaram(o)uche-8/15/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News